James Tyree Buys Shares of Genelux Corporation
James Tyree acquired 31,566 shares of Genelux on June 16, 2026.
Key Points
- James Tyree purchased 31,566 shares of Genelux Corporation on June 16, 2026, as part of insider buying activity.
- Genelux Corporation, trading at $2.97, has a market cap of approximately $133 million, with a 52-week range of $2.29 to $8.54.
- Peers like Vanguard Capital Management and Bleichroeder LP have also adjusted their positions in Genelux recently.
James Tyree recently increased his stake in Genelux Corporation by purchasing 31,566 shares on June 16, 2026. This insider buying activity was not planned and comes as the company continues to focus on its biopharmaceutical endeavors.
Other Institutional Activity in Genelux Corporation
Several institutional investors have also been active in Genelux Corporation. Vanguard Capital Management LLC added 1,695,480 shares, bringing its total to 1,695,480 shares valued at approximately $4.1 million. Bleichroeder LP increased its holdings by 666,666 shares, ending with 1,380,666 shares worth about $3.34 million. Geode Capital Management, LLC boosted its position by 72,354 shares to 453,761 shares, valued at nearly $1.1 million. Meanwhile, Bank of America Corp /DE/ trimmed its stake by 12,156 shares, holding 323,865 shares valued at $783,753.
Genelux Corporation Stock Snapshot
Shares of NasdaqCM:GNLX traded near $2.97. Genelux Corporation has a market cap of approximately $133 million and a forward P/E ratio of -3.9, indicating it is not currently profitable. The stock has a 52-week low of $2.29 and a high of $8.54, with a 50-day moving average of $2.84 and a 200-day moving average of $3.73. The company's current ratio is 3.68, and its debt-to-equity ratio stands at 10.89.
Insider Buying and Selling at Genelux Corporation
On June 16, 2026, several insiders, including James Tyree, John Smither, Mary Mirabelli, and Yong Yu, participated in buying shares of Genelux Corporation. Each of these insiders acquired 31,566 shares, while Yong Yu, the Chief Scientific Officer, purchased 119,318 shares. These transactions were not conducted under a Rule 10b5-1 plan.
Analysts Set New Price Targets
On March 20, 2026, Benchmark maintained its buy rating for Genelux Corporation with a price target of $20. Earlier, Lake Street initiated coverage on October 21, 2025, with a buy rating and a $16 target. The consensus among six analysts is a buy rating, with an average target price of $17.50.
About Genelux Corporation
Genelux Corporation is a clinical-stage biopharmaceutical company based in Westlake Village, California. It specializes in developing oncolytic viral immunotherapies for treating aggressive solid tumors. The company's leading product, Olvi-Vec, targets ovarian cancer. Genelux also operates the CHOICE platform for discovering and developing new therapies. With a team of 25 employees, the company is headed by CEO Thomas D. Zindrick.
Bottom Line
Insider buying by James Tyree and other executives highlights continued confidence in Genelux Corporation's potential. Investors often track such activities to gauge insider sentiment. It's important to remember that these transactions reflect past actions and may not indicate future trends.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.